Tue Sep 17 05:49:46 UTC 2024: ## Repare Therapeutics Sees Upgraded Earnings Forecast, Stock Remains “Buy”

**Toronto, Canada -** Repare Therapeutics Inc. (NASDAQ:RPTX) is seeing a positive outlook for its financial performance, with analysts at Bloom Burton raising their earnings per share (EPS) estimates for the company’s FY2024. Bloom Burton analyst D. Martin now forecasts a loss of ($1.94) per share, a significant improvement from their previous estimate of ($2.92).

The consensus estimate for Repare Therapeutics’ FY2024 earnings currently stands at ($2.31) per share. Several other analysts have also expressed positive sentiment towards the company, with Lifesci Capital upgrading the stock to a “strong-buy” and HC Wainwright reiterating a “buy” rating with a $10.00 price target. Overall, MarketBeat.com reports a consensus rating of “Buy” for RPTX, with a consensus price target of $17.33.

Repare Therapeutics, a clinical-stage precision oncology company, focuses on developing treatments targeting genomic instability through its proprietary SNIPRx platform. The company reported a loss of ($0.82) per share for the quarter ending August 6th, exceeding analysts’ expectations of ($0.85).

While the company’s recent performance and analyst upgrades indicate a positive trajectory, investors should note that Repare Therapeutics remains a development-stage company with a focus on research and development.

**Institutional investors continue to show interest in the company, with several acquiring new positions in RPTX stock in recent quarters. Notably, Bank of Montreal Can increased its holdings in Repare Therapeutics by 5.4% in the second quarter, reflecting confidence in the company’s future.**

The stock opened at $3.32 on Monday and has a market capitalization of $140.93 million.

Read More